Temozolomide - Standard format (pdf)
Find out more about Temozolomide in the full fact sheet
Temozolomide (TMZ) is a chemotherapy drug used to treat high grade brain tumours known as gliomas, particularly anaplastic astrocytoma (Grade 3) and glioblastoma (Grade 4). It has been shown to improve how long some people live with these types of fast-growing tumour.
TMZ is a type of chemotherapy drug known as an alkylating agent. This means it binds to the DNA in cells and interferes specifically with cell growth and division.
Unlike many other drugs, it is able to pass across the blood-brain barrier (BBB). This is a membrane of cells that blocks potentially harmful substances in the blood from entering the brain. Most other chemotherapy drugs are unable to pass across this membrane and reach the brain.
Sometimes, for some people, TMZ doesn't work so well. This depends to a large extent on the concentration and form of the MGMT protein (which repairs DNA) in the tumour. For more information on MGMT and how you can test for it, please see our information page on biomarkers.
Like all chemotherapy drugs, TMZ may cause one or more side-effects. The most common side-effect of this drug is an increased risk of developing a form of pneumonia known as Pneumonocystis Jirovecii Pneumonia or PCP. This is a fungal infection of the lungs which people with weakened immune systems are particularly susceptible to.For this reason your oncologist may prescribe a preventative antibiotic to reduce the chance of getting this infection. Other common side-effects of this drug include:
For a detailed list of side-effects, please see the drug's official information leaflet at: www.medicines.org.uk/emc/medicine/7027
If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:
0808 800 0004 (free from landlines and mobiles)
01252 749 999
Phone lines open Mon-Fri, 09:00-17:00
You can also join our active online community on Facebook - find out more about our groups.